New FDA approval for Pfizer’s RSV vaccine Abrysvo

The US Food and Drug Administration (FDA) yesterday approved Abrysvo (respiratory syncytial virus vaccine).

Developed and marketed by US pharma giant Pfizer (NYSA: PFE), the vaccine is now authorized for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.

According to Pfizer, Abrysvo now offers the broadest RSV vaccine indication for adults, which previously included those 60 years and older. Additionally, it remains the only RSV immunization approved for pregnant individuals at 32 through 36 weeks of gestation to protect infants from birth up to six months of age.